Momenta developed M118 using its proprietary technology for the detailed analysis and design of complex sugar therapeutics. By isolating, characterizing and engineering the key sugar structures within heparin
The approval follows a priority review of the company’s new drug application submission, which was granted in September 2005 to satisfy an unmet medical need in Japanese patients.
Under the agreement, Cimym will receive an up-front payment of $14.5 million and significant milestone payments at certain stages of development for each of a number of indications
Duetact combines Actos (pioglitazone HCl) and glimepiride, two widely used diabetes medications with complementary actions, in a single tablet. This brings together Actos’ ability to directly target insulin
HepeX-B is a combination of two fully human monoclonal antibodies that target the hepatitis B virus (HBV) surface. The product, which has been granted orphan drug status in
Azilect (rasagiline tablets) is indicated for use as initial monotherapy in early Parkinson’s disease (PD) and as adjunct therapy to levodopa in moderate-to-advanced disease. Teva has also launched
Auriga is among the first pharmaceutical companies to apply a commission-only structure. While many pharmaceutical companies compensate sales employees with an estimated 70% salary and the remainder in
Results of the 2,035-patient study, which was named NO16966, showed that the chemotherapy combination Xelox (Xeloda plus oxaliplati) is as effective in terms of progression-free survival (PFS) as
The Committee for Medicinal Products for Human Use (CHMP)’s recommendation is for the approval of Suboxone (buprenorphine hydrochloride/naloxone hydrochloride) sublingual tablets for the substitution treatment of opioid dependence,
The UK trial to evaluate TeGenero’s TGN1412 made the headlines earlier this year when six healthy study volunteers suffered multiple organ failure and were left fighting for their
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.